Best Androgen Receptor Inhibitor for prostatic neoplasms
3 Androgen Receptor Inhibitor drugs indicated for prostatic neoplasms, ranked by our independent rating. The current highest-rated is xtandi. Compare them with all treatments for prostatic neoplasms or the full Androgen Receptor Inhibitor class. Not medical advice — always consult a professional.
Top androgen receptor inhibitor for prostatic neoplasms: 1. Xtandi · 2. Enzalutamide · 3. Casodex
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Xtandi | 72/100 | Prescription | — | View → |
| 2 | Enzalutamide | 64/100 | Prescription | — | View → |
| 3 | Casodex |
Full ranking · 3 drugs
Frequently asked
- What is the best androgen receptor inhibitor for prostatic neoplasms?
- By our independent rating, xtandi currently ranks highest among Androgen Receptor Inhibitor drugs used for prostatic neoplasms. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which androgen receptor inhibitor drugs treat prostatic neoplasms?
- pharmaranks lists 3 Androgen Receptor Inhibitor products indicated for prostatic neoplasms, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
